Even through numerous combinations of chemotherapy regimens are used to treat on the advanced pancreatic cancer, APC; however, the survival rate (overall survival and progress free survival) and treatment-related toxicity remain challenge. Here we provided neutral and failed outcomes that treat the APC in clinical trials, this need us to think twice whether we were used the appropriate therapy regimens, to enlarge the survival rate and to reduce the treatment-related toxicity. Evidences of treatment on APC are need indeed to assistant our physician decision making correctly.

Biomarkers are emerging research filed in the past decade. Even though numerous biomarkers were reported, the efficiency of cancer therapy remains low. So the question emerges as to how much can we trust the current biomarkers on cancer therapy? In this upcoming chapter, we would like to illustrate the outcomes of classical cancer therapies on advanced pancreatic cancer disclosed successful, neutral and failed in clinical trials. The analysis will be carried on the perspective interdisciplinary on the biomarkers including anatomy, physiology, pharmacology, biochemistry, history path and development of pharmacy. Particular in-depth insight may open a window for new researches and lighting the therapies.